TISIDB

Summary
Symbol	OAT
Name	ornithine aminotransferase
Aliases	HOGA; ornithine aminotransferase precursor; gyrate atrophy; GACR; HOGAASE; OKT; ornithine delta-aminotransfe ......
Chromosomal Location	10q26
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway

> Subcellular Location, Domain and Function [ TOP ]
Subcellular Location	Mitochondrion matrix
Domain	PF00202 Aminotransferase class-III
Function	-

> Gene Ontology [ TOP ]
Biological Process	GO:0006520 cellular amino acid metabolic process GO:0006525 arginine metabolic process GO:0006527 arginine catabolic process GO:0006536 glutamate metabolic process GO:0006560 proline metabolic process GO:0006561 proline biosynthetic process GO:0007601 visual perception GO:0008652 cellular amino acid biosynthetic process GO:0009063 cellular amino acid catabolic process GO:0009064 glutamine family amino acid metabolic process GO:0009065 glutamine family amino acid catabolic process GO:0009084 glutamine family amino acid biosynthetic process GO:0010121 arginine catabolic process to proline via ornithine GO:0016053 organic acid biosynthetic process GO:0016054 organic acid catabolic process GO:0019493 arginine catabolic process to proline GO:0019544 arginine catabolic process to glutamate GO:0034214 protein hexamerization GO:0043648 dicarboxylic acid metabolic process GO:0044282 small molecule catabolic process GO:0044283 small molecule biosynthetic process GO:0046394 carboxylic acid biosynthetic process GO:0046395 carboxylic acid catabolic process GO:0050953 sensory perception of light stimulus GO:0051259 protein oligomerization GO:0055129 L-proline biosynthetic process GO:1901565 organonitrogen compound catabolic process GO:1901605 alpha-amino acid metabolic process GO:1901606 alpha-amino acid catabolic process GO:1901607 alpha-amino acid biosynthetic process
Molecular Function	GO:0004587 ornithine-oxo-acid transaminase activity GO:0008483 transaminase activity GO:0016769 transferase activity, transferring nitrogenous groups GO:0030170 pyridoxal phosphate binding GO:0043168 anion binding GO:0048037 cofactor binding
Cellular Component	GO:0005759 mitochondrial matrix

> KEGG and Reactome Pathway [ TOP ]
KEGG	hsa00330 Arginine and proline metabolism hsa01100 Metabolic pathways
Reactome	R-HSA-70614: Amino acid synthesis and interconversion (transamination) R-HSA-1430728: Metabolism R-HSA-71291: Metabolism of amino acids and derivatives

Summary
Symbol	OAT
Name	ornithine aminotransferase
Aliases	HOGA; ornithine aminotransferase precursor; gyrate atrophy; GACR; HOGAASE; OKT; ornithine delta-aminotransfe ......
Chromosomal Location	10q26
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Literatures that report relations between OAT and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.

> Text Mining [ TOP ]
There is no record.

Summary
Symbol	OAT
Name	ornithine aminotransferase
Aliases	HOGA; ornithine aminotransferase precursor; gyrate atrophy; GACR; HOGAASE; OKT; ornithine delta-aminotransfe ......
Chromosomal Location	10q26
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.

> High-throughput Screening

[ TOP ]

Statistical results of OAT in screening data sets for detecting immune reponses.

PMID	Screening System	Cancer Type	Cell Line	Data Set	Statistical Results	Relation to immunity
29301958	CRISPR-Cas9	melanoma	B16F10	Pmel-1 T cell	NA/NS	NA/NS
29301958	CRISPR-Cas9	melanoma	B16F10	OT-1 T cell	NA/NS	NA/NS
28783722	CRISPR-Cas9	melanoma	Mel624	2CT-CRISPR	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX+Anti-PD1	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX	NA/NS	NA/NS
25691366	RNAi	Breast cancer	MCF7	Luc-CTL assay	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Primary screen	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Secondary screen	NA/NS	NA/NS

Summary
Symbol	OAT
Name	ornithine aminotransferase
Aliases	HOGA; ornithine aminotransferase precursor; gyrate atrophy; GACR; HOGAASE; OKT; ornithine delta-aminotransfe ......
Chromosomal Location	10q26
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders

> Expression difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the expression difference of OAT in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	Log2 (Fold Change)	P value
1	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	14	12	0.396	0.226
2	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	6	5	0.787	0.776
3	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	7	0.116	0.953
4	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	-0.996	0.0549
5	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	-1.692	0.316
6	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	-0.115	0.958
7	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	26	23	-0.013	0.975
8	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	15	11	-0.093	0.962
9	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	11	12	0.103	0.961
10	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	4	8	0.149	0.931
11	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	2	0	0	1
12	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	2	8	0.562	0.83
13	29443960	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	68	230	-0.211	0.159

> Mutation difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the mutation difference of OAT in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	% Mut/Res	% Mut/NRes	% Diff (R vs NR)	Pval
1	25765070	Non-small cell lung cancer (NSCLC)	all	Anti-PD-1 (pembrolizumab)	14	17	0	0	0	1
2	25765070	Non-small cell lung cancer (NSCLC)	smoking	Anti-PD-1 (pembrolizumab)	10	3	0	0	0	1
3	25765070	Non-small cell lung cancer (NSCLC)	non-smoking	Anti-PD-1 (pembrolizumab)	4	14	0	0	0	1
4	26359337	Melanoma	all	Anti-CTLA-4 (ipilimumab)	27	73	11.1	0	11.1	0.0181
5	26359337	Melanoma	BRAFi	Anti-CTLA-4 (ipilimumab)	0	14	0	0	0	1
6	26359337	Melanoma	non-BRAFi	Anti-CTLA-4 (ipilimumab)	27	59	11.1	0	11.1	0.0286
7	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	21	17	0	0	0	1
8	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	6	0	0	0	1
9	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	13	11	0	0	0	1
10	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	0	6.2	-6.2	1
11	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	0	11.1	-11.1	1
12	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0	0	0	1
13	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	38	27	0	0	0	1
14	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	22	13	0	0	0	1
15	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	16	14	0	0	0	1
16	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	11	13	0	0	0	1
17	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	6	1	0	0	0	1
18	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	5	12	0	0	0	1

Summary
Symbol	OAT
Name	ornithine aminotransferase
Aliases	HOGA; ornithine aminotransferase precursor; gyrate atrophy; GACR; HOGAASE; OKT; ornithine delta-aminotransfe ......
Chromosomal Location	10q26
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of OAT. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.

> Lymphocyte [ TOP ]

Summary
Symbol	OAT
Name	ornithine aminotransferase
Aliases	HOGA; ornithine aminotransferase precursor; gyrate atrophy; GACR; HOGAASE; OKT; ornithine delta-aminotransfe ......
Chromosomal Location	10q26
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of OAT. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by OAT. > Immunoinhibitor > Immunostimulator > MHC molecule

> Immunoinhibitor [ TOP ]

> Immunostimulator [ TOP ]

> MHC molecule [ TOP ]

Summary
Symbol	OAT
Name	ornithine aminotransferase
Aliases	HOGA; ornithine aminotransferase precursor; gyrate atrophy; GACR; HOGAASE; OKT; ornithine delta-aminotransfe ......
Chromosomal Location	10q26
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of OAT. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor

> Chemokine [ TOP ]

> Receptor [ TOP ]

Summary
Symbol	OAT
Name	ornithine aminotransferase
Aliases	HOGA; ornithine aminotransferase precursor; gyrate atrophy; GACR; HOGAASE; OKT; ornithine delta-aminotransfe ......
Chromosomal Location	10q26
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Distribution of OAT expression across immune and molecular subtypes. > Immune subtype > Molecular subtype

> Immune subtype [ TOP ]

> Molecular subtype [ TOP ]

Summary
Symbol	OAT
Name	ornithine aminotransferase
Aliases	HOGA; ornithine aminotransferase precursor; gyrate atrophy; GACR; HOGAASE; OKT; ornithine delta-aminotransfe ......
Chromosomal Location	10q26
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Associations between OAT and clinical features. > Overall survival analysis > Cancer stage > Tumor grade

> Overall survival [ TOP ]

> Stage [ TOP ]

> Grade [ TOP ]

Summary
Symbol	OAT
Name	ornithine aminotransferase
Aliases	HOGA; ornithine aminotransferase precursor; gyrate atrophy; GACR; HOGAASE; OKT; ornithine delta-aminotransfe ......
Chromosomal Location	10q26
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Drugs targeting OAT collected from DrugBank database.

> Drugs from DrugBank database

[ TOP ]

Details on drugs targeting OAT.

ID	Name	Drug Type	Targets	#Targets
DB00114	Pyridoxal Phosphate	Small Molecule	AADAT, ABAT, AGXT, AGXT2, ALAS1, ALAS2, AZIN2, BCAT1, BCAT2, CBS, ......	54
DB00129	Ornithine	Small Molecule	ARG1, ARG2, GATM, OAT, OAZ1, OAZ2, OAZ3, OTC, SLC25A15, SLC25A2, S ......	14
DB02054	Gabaculine	Small Molecule	OAT	1
DB02821	Canaline	Small Molecule	OAT	1

Browse OAT